When combination therapy isn't working: Emerging therapies for the management of inflammatory bowel disease

World Journal of Gastroenterology

Volumn 20, Issue 5, 2014, Pages 1139-1146

  Krishnareddy, Suneeta ^a   Swaminath, Arun ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Emerging therapies; Inflammatory bowel disease; Tofacitinib; Ustekinumab; Vedolizumab

Indexed keywords

ADALIMUMAB; AGENTS USED IN INFLAMMATORY BOWEL DISEASE; ALPHA4 INTEGRIN; BRIAKINUMAB; CELL ADHESION MOLECULE; CERTOLIZUMAB; CORTICOSTEROID; CP550; CP690; GOLIMUMAB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; JANUS KINASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NATALIZUMAB; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; PREDNISONE; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; USTEKINUMAB; VEDOLIZUMAB;

ARTICLE; BONE MARROW SUPPRESSION; CROHN DISEASE; DIABETES MELLITUS; DISEASE ACTIVITY; FEVER; GENE MUTATION; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE EPITHELIUM; LIVER TOXICITY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHODGKIN LYMPHOMA; OSTEOPOROSIS; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED STUDY (TOPIC); RHEUMATOID ARTHRITIS; RISK FACTOR; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EMERGING THERAPIES; INFLAMMATORY BOWEL DISEASE; TOFACITINIB; USTEKINUMAB; VEDOLIZUMAB;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DRUG DESIGN; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

EID: 84893095796     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i5.1139     Document Type: Article

References (53)

1. Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 2013; 62: 1505-1510 [PMID: 24037875 DOI:10.1136/gutjnl-2012-303954]
2. Girardin M, Manz M, Manser C, Biedermann L, Wanner R, Frei P, Safroneeva E, Mottet C, Rogler G, Schoepfer AM. First-line therapies in inflammatory bowel disease. Digestion 2012; 86 Suppl 1: 6-10 [PMID: 23051720 DOI:10.1159/000341951]
3. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P. Infliximab, azathioprine, or combination therapy for Crohn' s disease. N Engl J Med 2010; 362: 1383-1395 [PMID: 20393175 DOI: 10.1056/NEJMoa0904492]
4. Korelitz BI, Lindner AE. The Influence of Corticotrophin and Adrenal Steroids of the Course of Ulcerative Colitis: A Comparison with the Presteroid Era. Gastroenterology 1964; 46: 671-679 [PMID: 14173925]
5. Warren BF, Watkins PE. Effect of steroids in an IBD model. Aliment Pharmacol Ther 1993; 7: 585-586 [PMID: 8280826 DOI:10.1111/j.1365-2036.1993.tb00078.x]
6. Lukáš K, Dastych M, Novotný A, Prokopová L, Zbořil V. Long-term therapy of idiopathic inflammatory bowel disease. Cas Lek Cesk 2012; 151: 231-242 [PMID: 22779764]
7. Neurath M. Thiopurines in IBD: What Is Their Mechanism of Action? Gastroenterol Hepatol (N Y) 2010; 6: 435-436 [PMID: 20827366]
8. Sandborn WJ. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl 1998; 225: 92-99 [PMID: 9515759 DOI: 10.1080/003655298750027290]
9. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 874-881 [PMID: 19558997 DOI: 10.1016/ j.cgh.2009.01.004]
10. Jorquera A, Solari S, Vollrath V, Guerra I, Chianale J, Cofré C, Kalergis A, Ibáñez P, Bueno S, Alvarez-Lobos M. Phenotype and genotype of thiopurine methyltransferase in Chilean individuals. Rev Med Chil 2012; 140: 889-895 [PMID: 23282701 DOI: 10.4067/S0034-98872012000700009]
11. de Beaumais TA, Fakhoury M, Pigneur B, Viola S, Medard Y, Broly F, Jacqz-Aigrain E. Characterization of a novel TPMT mutation associated with azathioprine-induced myelosuppression. Br J Clin Pharmacol 2009; 68: 770-772 [PMID: 19917002 DOI: 10.1111/j.1365-2125.2009.03439.x]
12. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353-356 [PMID: 2492786 DOI: 10.7326/0003-4819-110-5-353]
13. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2003; (1): CD003459 [PMID: 12535475]
14. Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011; 106 Suppl 1: S2-25; quiz S26 [PMID: 21472012]
15. Swaminath A, Lebwohl B, Capiak KM, Present DH. Practice patterns in the use of anti-tumor necrosis factor alpha agents in the management of Crohn's disease: a US national practice survey comparing experts and non-experts. Dig Dis Sci 2011; 56: 1160-1164 [PMID: 21181440 DOI: 10.1007/ s10620-010-1530-9]
16. D'Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 2006; 8: 506-512 [PMID: 17105690 DOI: 10.1007/ s11894-006-0041-5]
17. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644-659, quiz 660 [PMID: 21407183 DOI: 10.1038/ajg.2011.73]
18. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a metaanalysis. Am J Gastroenterol 2013; 108: 40-47; quiz 48 [PMID: 23147525 DOI: 10.1038/ajg.2012.363]
19. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011; 106: 685-698 [PMID: 21427713 DOI: 10.1038/ajg.2011.103]
20. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925 [PMID: 16267322 DOI: 10.1056/NEJMoa043335]
21. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007; 132: 1672-1683 [PMID: 17484865 DOI: 10.1053/ j.gastro.2007.03.024]
22. Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Gastroenterol Clin North Am 2009; 38: 577-594 [PMID: 19913203 DOI: 10.1016/j.gtc.2009.07.007]
23. D'Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol 2010; 7: 86-92 [PMID: 20134490 DOI: 10.1038/nrgastro.2009.222]
24. D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106: 199-212; quiz 213 [PMID: 21045814 DOI: 10.1038/ajg.2010.392]
25. Schwartz DA, Loftus EV, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002; 122: 875-880 [PMID: 11910338 DOI: 10.1053/gast.2002.32362]
26. Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lémann M. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011; 17: 1415-1422 [PMID: 21560202 DOI: 10.1002/ibd.21506]
27. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010; 59: 1200-1206 [PMID: 20650924 DOI: 10.1136/ gut.2009.202101]
28. Sandborn WJ. Step-up versus top-down therapy in the treatment of ulcerative colitis. Gastroenterol Hepatol (N Y) 2007; 3: 16-17 [PMID: 21960772]
29. Shih DQ, Targan SR, McGovern D. Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep 2008; 10: 568-575 [PMID: 19006613 DOI: 10.1007/ s11894-008-0104-x]
30. Guerra JF, Zasloff M, Lough D, Abdo J, Hawksworth J, Mastumoto C, Girlanda R, Island E, Shetty K, Kaufman S, Fishbein T. Nucleotide oligomerization domain 2 polymorphisms in patients with intestinal failure. J Gastroenterol Hepatol 2013; 28: 309-313 [PMID: 23173613]
31. Benor S, Russell GH, Silver M, Israel EJ, Yuan Q, Winter HS. Shortcomings of the inflammatory bowel disease Serology 7 panel. Pediatrics 2010; 125: 1230-1236 [PMID: 20439597 DOI:10.1542/peds.2009-1936]
32. Sandborn WJ. Serologic markers in inflammatory bowel disease: state of the art. Rev Gastroenterol Disord 2004; 4: 167-174 [PMID: 15580151]
33. Dubinsky MC. Clinical perspectives in Crohn's disease: Serologic and prognostic biomarkers: who, when, and how? Rev Gastroenterol Disord 2007; 7 Suppl 2: S3-S7 [PMID: 17392637]
34. Romberg-Camps MJ, Dagnelie PC, Kester AD, Hesselinkvan de Kruijs MA, Cilissen M, Engels LG, Van Deursen C, Hameeteman WH, Wolters FL, Russel MG, Stockbrügger RW. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009; 104: 371-383 [PMID: 19174787 DOI: 10.1038/ajg.2008.38]
35. Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol 2013; 29: 397-404 [PMID: 23695427 DOI:10.1097/MOG.0b013e3283622914]
36. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-250 [PMID: 12131607 DOI: 10.1097/00054725-200207000-00002]
37. Danese S, Colombel JF, Peyrin-Biroulet L, Rutgeerts P, Reinisch W. Review article: the role of anti-TNF in the management of ulcerative colitis -- past, present and future. Aliment Pharmacol Ther 2013; 37: 855-866 [PMID: 23489068 DOI:10.1111/apt.12284]
38. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65 [PMID: 17241859 DOI: 10.1053/j.gastro.2006.11.041]
39. Hutas G. Golimumab as the first monthly subcutaneous fully human anti-TNF-alpha antibody in the treatment of inflammatory arthropathies. Immunotherapy 2010; 2: 453-460 [PMID: 20635999 DOI: 10.2217/imt.10.34]
40. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-238 [PMID: 17634458 DOI: 10.1056/NEJMoa067594]
41. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549 [PMID: 12047962 DOI: 10.1016/S0140-6736(02)08512-4]
42. Zhernakova A, Festen EM, Franke L, Trynka G, van Diemen CC, Monsuur AJ, Bevova M, Nijmeijer RM, van't Slot R, Heijmans R, Boezen HM, van Heel DA, van Bodegraven AA, Stokkers PC, Wijmenga C, Crusius JB, Weersma RK. Genetic analysis of innate immunity in Crohn's disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. Am J Hum Genet 2008; 82: 1202-1210 [PMID: 18439550 DOI: 10.1016/j.ajhg.2008.03.016]
43. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367: 1519-1528 [PMID: 23075178 DOI:10.1056/NEJMoa1203572]
44. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135: 1130-1141 [PMID: 18706417 DOI: 10.1053/j.gastro.2008.07.014]
45. Löwenberg M, D'Haens G. Novel targets for inflammatory bowel disease therapeutics. Curr Gastroenterol Rep 2013; 15: 311 [PMID: 23314806 DOI: 10.1007/s11894-012-0311-3]
46. Perrier C, Rutgeerts P. New drug therapies on the horizon for IBD. Dig Dis 2012; 30 Suppl 1: 100-105 [PMID: 23075877 DOI: 10.1159/000341133]
47. Allen PB. Anti-adhesion molecules: is gut specificity the key for a good safety profile? Curr Drug Deliv 2012; 9: 333-337. [PMID: 22762276 DOI: 10.2174/156720112801323143]
48. Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, Ponich T, Fox I, Feagan BG. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012; 18: 1470-1479 [PMID: 22147460 DOI: 10.1002/ibd.21896]
49. Mosli MH, Feagan BG. Vedolizumab for Crohn's disease. Expert Opin Biol Ther 2013; 13: 455-463 [PMID: 23394379 DOI:10.1517/14712598.2013.770835]
50. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710 [PMID: 23964932 DOI: 10.1056/ NEJMoa1215734]
51. Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res 2013; 76: 1-8 [PMID: 23827161 DOI: 10.1016/j.phrs.2013.06.007]
52. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367: 616-624 [PMID: 22894574 DOI: 10.1056/NEJMoa1112168]
53. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A., Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369: 711-721 [PMID: 23964933 DOI: 10.1056/NEJMoa1215739]